Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q1 FY21 results · Apr–Jun 2020
Caplin Point Laboratories reported revenue from operations of ₹1.20 crore (down 99.1% from Q1 FY20) and net profit of ₹0.42 crore (down 99.3% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.20 | 140.27 | −99.1% | 100.12 | −98.8% |
| Other income | 0.04 | 19.94 | −99.8% | 33.01 | −99.9% |
| Total income | 1.24 | 160.21 | −99.2% | 133.14 | −99.1% |
| Profit before tax | 0.56 | 74.03 | −99.2% | 65.81 | −99.1% |
| Net profit for the period | 0.42 | 60.11 | −99.3% | 50.15 | −99.2% |
| EPS, basic (₹) | 5.55 | 7.95 | not comparable | 6.63 | not comparable |
| Net margin (%) | 35.1 | 42.9 | 50.1 |
Standalone
- Filed with BSE
- 11 Aug 2020, 16:56 IST
- Board meeting
- 10 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE